Last reviewed · How we verify
EVT801
At a glance
| Generic name | EVT801 |
|---|---|
| Sponsor | Kazia Therapeutics Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVT801 CI brief — competitive landscape report
- EVT801 updates RSS · CI watch RSS
- Kazia Therapeutics Limited portfolio CI